Webb Robert Thomas 4

What Happened
Webb Robert Thomas, a director of Ardent Health, reported an award acquisition of 14,231 restricted stock units (RSUs) on April 1, 2026. The filing lists an acquisition price of $0.00 (typical for RSU grants); the economic value will depend on Ardent Health's future stock price when the RSUs vest.

Key Details

• Transaction date: 2026-04-01; Report filed: 2026-04-02 (Form 4 accession 0001628280-26-023271).
• Amount: 14,231 RSUs; reported price: $0.00.
• Vesting: Per footnote, the RSUs "vest in full on the first anniversary of April 1, 2026" (i.e., April 1, 2027), subject to continued service.
• Shares owned after transaction: not disclosed in this Form 4.
• Filing timeliness: Filed the next day (no late filing flag on the report).

Context
These are restricted stock units (a grant), not an open-market purchase or sale. RSUs convert to actual shares only upon vesting (subject to service conditions), so this does not represent an immediate cash outlay or a liquidity event. Grants are a routine form of equity compensation and align executive/director interests with shareholders but do not alone indicate buying/selling sentiment.